WO2009070609A3 - Therapeutic targeting of il-6 using sirna in neutral liposomes - Google Patents
Therapeutic targeting of il-6 using sirna in neutral liposomes Download PDFInfo
- Publication number
- WO2009070609A3 WO2009070609A3 PCT/US2008/084742 US2008084742W WO2009070609A3 WO 2009070609 A3 WO2009070609 A3 WO 2009070609A3 US 2008084742 W US2008084742 W US 2008084742W WO 2009070609 A3 WO2009070609 A3 WO 2009070609A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- sirna
- therapeutic targeting
- neutral liposomes
- component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed are compositions that include a nucleic acid component that include a nucleic acid that inhibits the expression of a gene that encodes interleukin-6 (IL-6), and a lipid component that includes one or more phospholipids. Also disclosed are methods of treating a subject with cancer that exhibits stress-related growth involve administering to the subject a pharmaceutically effective amount of a composition that includes a nucleic acid component that includes a nucleic acid that inhibits the expression of a gene that encodes IL- 6, and a lipid component comprising one or more phospholipids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99053807P | 2007-11-27 | 2007-11-27 | |
US60/990,538 | 2007-11-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009070609A2 WO2009070609A2 (en) | 2009-06-04 |
WO2009070609A3 true WO2009070609A3 (en) | 2010-09-10 |
Family
ID=40524697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/084742 WO2009070609A2 (en) | 2007-11-27 | 2008-11-25 | Therapeutic targeting of il-6 using sirna in neutral liposomes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009070609A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10214983A1 (en) | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Nebulisable liposomes and their use for pulmonary application of active substances |
CN101579329B (en) * | 2009-06-08 | 2011-11-09 | 沈阳亿灵医药科技有限公司 | Bevantolol hydrochloride sustained release preparation |
DE102009031274A1 (en) | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomes for pulmonary application |
CL2011000273A1 (en) * | 2011-02-08 | 2011-06-17 | Univ Pontificia Catolica Chile | Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer. |
WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
CN103536594A (en) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | Application of G-protein-coupled receptor antagonist in preparing medicine for treating glutamate receptor high-expression tumor |
CN114224875B (en) * | 2021-11-04 | 2023-08-11 | 中南大学湘雅医院 | New use of alcohol compound and antitumor drug |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113679A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
-
2008
- 2008-11-25 WO PCT/US2008/084742 patent/WO2009070609A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113679A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
Non-Patent Citations (2)
Title |
---|
LANDEN CHARLES N JR ET AL: "Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.", 1 November 2007, CANCER RESEARCH 1 NOV 2007, VOL. 67, NR. 21, PAGE(S) 10389 - 10396, ISSN: 1538-7445, XP002575012 * |
NILSSON MONIQUE B ET AL: "Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.", THE JOURNAL OF BIOLOGICAL CHEMISTRY IN PRESS, no. M611539200, 23 August 2007 (2007-08-23), pages 1 - 19, XP002574048, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org/content/early/2007/08/23/jbc.M611539200> [retrieved on 20100318], DOI: 10.1074/jbc.M611539200 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009070609A2 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009070609A3 (en) | Therapeutic targeting of il-6 using sirna in neutral liposomes | |
WO2008109432A3 (en) | Therapeutic targeting of interleukins using sirna in neutral liposomes | |
WO2009149418A3 (en) | Compositions for the in vivo delivery of rnai agents | |
WO2007117686A3 (en) | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 | |
WO2018140920A8 (en) | Compositions and methods for inhibition of factor xii gene expression | |
WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
EP2348112A3 (en) | Stabilized immune modulatory RNA (SIMRA) compounds | |
WO2006113679A3 (en) | Delivery of sirna by neutral lipid compositions | |
WO2006119958A3 (en) | Use of flibanserin in the treatment of chronic pain | |
WO2004084950A3 (en) | Cell targeting methods and compositions | |
WO2007064857A8 (en) | Amphoteric liposome formulation | |
WO2011035335A3 (en) | Stabilized liquid and lyophilized adamts13 formulations | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
WO2006099169A3 (en) | Novel liposome compositions | |
MX348817B (en) | Methods for treating cancer and non-neoplastic conditions. | |
AU2009303344A8 (en) | Targeting of antigen presenting cells with immunonanotherapeutics | |
WO2008042973A3 (en) | Lipid containing formulations | |
WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
MX2011003843A (en) | Adjuvant incorporation in immunonanotherapeutics. | |
WO2006055352A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally | |
WO2009055568A3 (en) | Liposomal vancomycin formulations | |
MX2009013815A (en) | Quinazolinone compounds and methods of use thereof. | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
WO2009114475A3 (en) | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use | |
WO2009129387A3 (en) | Cationic lipids and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08855077 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08855077 Country of ref document: EP Kind code of ref document: A2 |